SecBot SecBot
144 ·Filed Jul 23, 2026

IRD

Opus Genetics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001974078-26-000274
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine tax-withholding sale tied to RSU vesting, not a discretionary insider sale. No bearish signal. Monitor for any future discretionary Form 4 filings by the officer for a change in sentiment.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d ⚠ clustered
IRD ▲ +38.70% at T+60d
NEUTRAL call +38.70% · α vs SPY +34.15% · entry $2.92 → $4.05
Entry = T+0 close
Jul 23, 2026
via day close
T+1d
+5.48%
call +5.48% · α +5.38%
$3.08
settled 3mo ago
T+5d
+31.51%
call +31.51% · α +31.03%
$3.84
settled 3mo ago
T+20d
+41.10%
call +41.10% · α +37.79%
$4.12
settled 2mo ago
T+60d
+38.70%
call +38.70% · α +34.15%
$4.05
settled 11d ago

Price Chart

Loading chart...

Executive Summary

Joseph K. Schachle, an officer of Opus Genetics, filed a Form 144 notice of intent to sell 4,644 shares of common stock, with an approximate market value of $13,653. The sale is non-discretionary, required to cover tax obligations related to the vesting of 15,625 RSUs. The filing is a routine tax-withholding sale and does not signal a change in the insider's view of the company's prospects.

Key Facts

  • Joseph K. Schachle, an officer of Opus Genetics, filed a Form 144 to sell 4,644 shares.
  • The approximate market value of the proposed sale is $13,653.36.
  • The sale is required to cover tax obligations from the vesting of 15,625 RSUs on July 22, 2026.
  • The sale is non-discretionary and is being executed through Raymond James & Associates.

Financial Impact

The proposed sale of $13,653 is immaterial relative to the company's $253M market cap.

dilution

Risk Factors

  • The sale, while routine, adds a small amount of sell-side pressure.
  • If the officer files a discretionary Form 4 in the future, it could signal a change in conviction.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001974078-26-000274
Document: 0001974078-26-000274-index.html0001974078-26-000274
Document: 0001974078-26-000274.txt0001974078-26-000274
25 reports for IRD
Performance horizon
50% Hit rate @ T+60 2 of 4 directional calls Went positive at some point 5 of 8 best @ T+60▲ +28.19%May 12, 2026
Filters
Rows
Reports for IRD — sortable, filterable
TypeNow
Oct 23, 2026
3d ago
144
NEUTRAL ★ 2/10
$3.52awaiting T+60—$3.32 (−5.68%)
Oct 21, 2026
5d ago
8-K
NEUTRAL ★ 2/10
$3.82awaiting T+60—$3.32 (−13.09%)
Oct 15, 2026
11d ago
8-K
BULLISH ★ 6/10
$3.84awaiting T+60—$3.32 (−13.54%)
Oct 15, 2026
11d ago
Press Release
BULLISH ★ 6/10
$3.84awaiting T+60—$3.32 (−13.54%)
Sep 22, 2026
4w ago
Institutional Cluster
NEUTRAL ★ 3/10
$5.16awaiting T+60—$3.32 (−35.66%)
Sep 11, 2026
6w ago
8-K
BULLISH ★ 7/10
$6.04awaiting T+60—$3.32 (−45.03%)
Sep 9, 2026
6w ago
8-K
BULLISH ★ 7/10
$5.73awaiting T+60—$3.32 (−42.06%)
Sep 2, 2026
7w ago
Press Release
NEUTRAL ★ 5/10
$4.45awaiting T+60—$3.32 (−25.39%)
Aug 6, 2026
11w ago
8-K
NEUTRAL ★ 5/10
$3.72awaiting T+60—$3.32 (−10.75%)
Jul 23, 2026
13w ago
144
NEUTRAL ★ 2/10
$2.92 $4.05▲ +38.70%▲ +34.15%$3.32 (+13.70%)
Showing 10 of 25

US Market Status

Market Closed — Opens in 7h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 23, 2026